Thomas Soloway, T-knife CEO
What happens when you give a mouse a human self-antigen? Investors bet $110M to find out
T-knife Therapeutics launched last August on a mission to isolate T cell receptors not from human donors, but from mice. Now, with a new CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
